Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Total Current Liabilities of $9.9 million for Q1 2026, down 91.06% year-over-year from $110.7 million in Q1 2025, and down 52.57% quarter-over-quarter from $20.9 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Total Current Liabilities for 17 consecutive years, with $9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 91.06% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (down 91.06% YoY), while the FY2025 annual figure was $20.9 million, down 53.88% from the prior year.
- Total Current Liabilities eased to $9.9 million in Q1 2026 per LXRX's latest filing, from $20.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $110.7 million in Q1 2025 and bottomed at $9.9 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $30.5 million across 5 years, with a median of $23.4 million in 2024.
- Annual changes were most pronounced in 2025 — Total Current Liabilities jumped 373.07% — and 2026, when it slumped 91.06%.
- Lexicon Pharmaceuticals' Total Current Liabilities stood at $23.2 million in 2022, then jumped by 36.14% to $31.5 million in 2023, then jumped by 43.43% to $45.2 million in 2024, then sank by 53.88% to $20.9 million in 2025, then plunged by 52.57% to $9.9 million in 2026.
- Business Quant data shows LXRX's Total Current Liabilities at $9.9 million in Q1 2026, $20.9 million in Q4 2025, and $21.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 14.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.71 Mn |
| Mar 31, 2026 | 9.90 Mn |
| Dec 31, 2025 | 20.87 Mn |
| Sep 30, 2025 | 21.72 Mn |
| Jun 30, 2025 | 34.84 Mn |
| Mar 31, 2025 | 110.69 Mn |
| Dec 31, 2024 | 45.25 Mn |
| Sep 30, 2024 | 36.05 Mn |
| Jun 30, 2024 | 27.88 Mn |
| Mar 31, 2024 | 23.40 Mn |
| Dec 31, 2023 | 31.55 Mn |
| Sep 30, 2023 | 32.26 Mn |
| Jun 30, 2023 | 26.11 Mn |
| Mar 31, 2023 | 20.37 Mn |
| Dec 31, 2022 | 23.17 Mn |
| Sep 30, 2022 | 18.45 Mn |
| Jun 30, 2022 | 16.86 Mn |
| Mar 31, 2022 | 18.91 Mn |
| Dec 31, 2021 | 22.12 Mn |
| Sep 30, 2021 | 34.25 Mn |